EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders

Giorgia Dinoi iD, Ileana Canfora iD, Daniela D'Agnano, Brigida Boccanegra iD, Elena Conte iD, Annamaria De Luca iD, Antonella Liantonio iD, Vittorio Sciruicchio iD, Paola Imbrici iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Giorgia Dinoi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona 4, 70125 Bari, Italy. Hauptthemen laut MEDLINE: Sodium Channels, Epilepsies, Myoclonic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - Next Generation EU - Ministero della Salute PNRR M6/C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, NEXTGENERATIONEU (NGEU), Italian Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), European Union—Next Generation EU—Ministero della Salute PNRR M6/C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Variants in neuronal sodium channel genes are responsible for a spectrum of neurological disorders, including developmental and epileptic encephalopathies (DEEs), with considerable genetic and phenotypic heterogeneity and drug resistance. Gene variants can produce loss-, gain-, or mixed-function effects, resulting in complex genotype-phenotype correlations. Current treatments rely mainly on symptomatic polytherapy with antiseizure medications, with sodium channel blockers contraindicated in loss-of-function cases but beneficial in gain-of-function forms. Existing therapies often provide limited benefit or even no seizure control at all and fail to address developmental impairments, highlighting the need for novel approaches. Emerging strategies include antisense oligonucleotides, gene therapy, and selective small-molecule modulators, which have shown antiseizure potential in preclinical models and in initial clinical studies by modulating SCN gene expression and function. Additionally, pharmacological agents such as fenfluramine, stiripentol, and cannabidiol, although not acting directly on sodium channels, represent recognized therapeutic options for SCN1A-related Dravet syndrome. This review summarizes recent advances in approved and investigational treatments for sodium channel-related neurological disorders, highlighting the transition from symptomatic to precision therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium ChannelsEpilepsies, MyoclonicHumansAnimalsGenetic TherapySodium Channel BlockersNAV1.1 Voltage-Gated Sodium ChannelAnticonvulsantsOligonucleotides, AntisenseNeurons

Stichwörter der Autor:innen

Dravet syndromeETX-101elsunersenfenfluraminesodium channelszorevunersen

Substanzen

Sodium ChannelsSodium Channel BlockersNAV1.1 Voltage-Gated Sodium ChannelAnticonvulsantsOligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona 4, 70125 Bari, Italy.
  • Children Epilepsy and EEG Center, San Paolo Hospital, ASL Bari, 70132 Bari, Italy.

ORCID-Profile: Giorgia Dinoi, Ileana Canfora, Brigida Boccanegra, Elena Conte, Annamaria De Luca, Antonella Liantonio, Vittorio Sciruicchio, Paola Imbrici

Förderung

  • European Union - Next Generation EU - Ministero della Salute PNRR M6/C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
  • NEXTGENERATIONEU (NGEU), Italian Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP)
  • European Union—Next Generation EU—Ministero della Salute PNRR M6/C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
  • NEXTGENERATIONEU

Zitieren

APA

Dinoi, G., Canfora, I., D'Agnano, D., Boccanegra, B., Conte, E., De Luca, A., Liantonio, A., Sciruicchio, V., & Imbrici, P. (2025). From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010032

Vancouver

Dinoi G, Canfora I, D'Agnano D, Boccanegra B, Conte E, De Luca A, et al. From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010032

BibTeX
@article{Dinoi2025,
  author = {Dinoi, Giorgia and Canfora, Ileana and D'Agnano, Daniela and Boccanegra, Brigida and Conte, Elena and De Luca, Annamaria and Liantonio, Antonella and Sciruicchio, Vittorio and Imbrici, Paola},
  title = {From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010032}
}
Kostenlos starten →